trastuzumab
Selected indexed studies
- Trastuzumab Deruxtecan: First Approval. (Drugs, 2020) [PMID:32144719]
- Trastuzumab-Induced Cardiomyopathy. (Cardiol Clin, 2019) [PMID:31587782]
- Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. (Cancer Commun (Lond), 2023) [PMID:37434399]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Trastuzumab Deruxtecan: First Approval. (2020) pubmed
- Trastuzumab-Induced Cardiomyopathy. (2019) pubmed
- Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. (2023) pubmed
- Trastuzumab administration during pregnancy: an update. (2021) pubmed
- Trastuzumab Cardiotoxicity: Mechanism and Management. (2025) pubmed
- Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma. (2023) pubmed
- Trastuzumab deruxtecan for HER2+ advanced breast cancer. (2022) pubmed
- Trastuzumab/Hyaluronidase-oysk: A New Option for Patients With HER2-Positive Breast Cancer. (2020) pubmed
- Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. (2008) pubmed
- Trastuzumab-associated cardiotoxicity. (2002) pubmed